Lacnotuzumab - Novartis Oncology

Drug Profile

Lacnotuzumab - Novartis Oncology

Alternative Names: MCS110

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Phase I/II Solid tumours
  • Discontinued Bone metastases; Prostate cancer

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase Ib/II trial solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 07 Mar 2018 Novartis in collaboration with Dana-Farber Cancer Institute plans a phase I/II trial for Malignant melanoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA in March 2018 (NCT03455764)
  • 22 Sep 2017 Washington University School of Medicine in collaboration with Novartis Pharmaceuticals plans a phase I trial (Combination therapy) for Breast cancer in USA in December 2017 (NCT03285607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top